AU2002230869A1 - Antisense modulation of hepsin expression - Google Patents
Antisense modulation of hepsin expressionInfo
- Publication number
- AU2002230869A1 AU2002230869A1 AU2002230869A AU3086902A AU2002230869A1 AU 2002230869 A1 AU2002230869 A1 AU 2002230869A1 AU 2002230869 A AU2002230869 A AU 2002230869A AU 3086902 A AU3086902 A AU 3086902A AU 2002230869 A1 AU2002230869 A1 AU 2002230869A1
- Authority
- AU
- Australia
- Prior art keywords
- antisense modulation
- hepsin expression
- hepsin
- expression
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004989 Hepsin Human genes 0.000 title 1
- 108090001101 Hepsin Proteins 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/742,703 US6423543B1 (en) | 2000-12-20 | 2000-12-20 | Antisense modulation of hepsin expression |
| US09/742,703 | 2000-12-20 | ||
| PCT/US2001/048431 WO2002050248A2 (en) | 2000-12-20 | 2001-12-14 | Antisense modulation of hepsin expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002230869A1 true AU2002230869A1 (en) | 2002-07-01 |
Family
ID=24985879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002230869A Abandoned AU2002230869A1 (en) | 2000-12-20 | 2001-12-14 | Antisense modulation of hepsin expression |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6423543B1 (en) |
| AU (1) | AU2002230869A1 (en) |
| WO (1) | WO2002050248A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003016484A2 (en) * | 2001-08-17 | 2003-02-27 | Affymetrix, Inc. | Gleason grade 4/5 prostate cancer genes |
| US20040029151A1 (en) * | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| US20050272052A1 (en) * | 2002-04-09 | 2005-12-08 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| WO2004086035A1 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with hepsin (hpn) |
| US7029675B1 (en) | 2003-06-04 | 2006-04-18 | Shu-Wha Lin | Hepsin antagonist and methods of use |
| MX2007001064A (en) * | 2004-07-26 | 2007-04-12 | Genentech Inc | Methods and compositions for modulating hepatocyte growth factor activation. |
| EP2462937A1 (en) * | 2005-05-24 | 2012-06-13 | Isis Pharmaceuticals, Inc. | Modulation of LMW-PTPase Expression |
| AU2007260953B2 (en) * | 2006-06-22 | 2013-07-11 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator |
| CA2656168A1 (en) | 2006-06-22 | 2007-12-27 | Genentech, Inc. | Methods and compositions for targeting hepsin |
| US20100280139A1 (en) * | 2009-04-30 | 2010-11-04 | Bayer Materialscience Llc | Sprayable elastomeric polyurethane foam and process for its production |
| US20100279101A1 (en) * | 2009-04-30 | 2010-11-04 | Bayer Materialscience Llc | Composites produced from sprayable elastomeric polyurethane foam |
| WO2017162659A1 (en) | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Intracellular hepsin as therapeutic target for the treatment of cancer with centrosome amplification |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981830A (en) * | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
-
2000
- 2000-12-20 US US09/742,703 patent/US6423543B1/en not_active Expired - Fee Related
-
2001
- 2001-12-14 WO PCT/US2001/048431 patent/WO2002050248A2/en not_active Ceased
- 2001-12-14 AU AU2002230869A patent/AU2002230869A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002050248A2 (en) | 2002-06-27 |
| WO2002050248A3 (en) | 2003-01-03 |
| US6423543B1 (en) | 2002-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
| AU2001294926A1 (en) | Antisense modulation of smad6 expression | |
| AU2001277054A1 (en) | Antisense modulation of lysophospholipase i expression | |
| AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
| AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
| AU2002309819A1 (en) | Antisense modulation of PTP1B expression | |
| AU2001261808A1 (en) | Antisense modulation of pten expression | |
| AU2001289046A1 (en) | Antisense modulation of her-2 expression | |
| AU2001229447A1 (en) | Antisense modulation of smad7 expression | |
| AU5788599A (en) | Antisense modulation of interleukin-15 expression | |
| AU2001278077A1 (en) | Antisense modulation of ptp1b expression | |
| AU2001239971A1 (en) | Antisense modulation of parp expression | |
| AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
| AU6115400A (en) | Antisense modulation of mekk5 expression | |
| AU2002230869A1 (en) | Antisense modulation of hepsin expression | |
| AU2002366788A1 (en) | Antisense modulation of ship-1 expression | |
| AU2001288968A1 (en) | Antisense modulation of btak expression | |
| AU2002318139A1 (en) | Antisense modulation of src-c expression | |
| AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression | |
| AU2002226064A1 (en) | Antisense modulation of talin expression | |
| AU5486700A (en) | Antisense modulation of g-alpha-s1 expression | |
| AU2002357102A1 (en) | Antisense modulation of cd36l1 expression | |
| AU2001287136A1 (en) | Antisense modulation of glioma-associated oncogene-1 expression | |
| AU2410600A (en) | Antisense modulation of g-alpha-i3 expression | |
| AU2001296731A1 (en) | Antisense modulation of bcas1 expression |